- Home
- KRNY vs LYEL Comparison
KRNY vs LYEL Comparison
Compare KRNY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRNY | LYEL |
|---|---|---|
| Founded | 1884 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.6M | 490.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KRNY | LYEL |
|---|---|---|
| Price | $7.25 | $21.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 272.1K | 96.5K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | ★ 130.22 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,580,000.00 | $61,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $24.37 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.45 | $0.39 |
| 52 Week High | $8.50 | $45.00 |
Technical Indicators
Market Signals| Indicator | KRNY | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 40.46 |
| Support Level | $6.30 | $15.82 |
| Resistance Level | $8.42 | $27.30 |
| Average True Range (ATR) | 0.23 | 1.85 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 6.90 | 3.97 |
Price Performance
Historical ComparisonAbout KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.